142 related articles for article (PubMed ID: 38431592)
1. Diagnostic value of plasma-derived exosomal miR-223 for epithelial ovarian cancer.
Yang L; Yang Z; Liu Z; Qi N; Tao L
BMC Womens Health; 2024 Mar; 24(1):150. PubMed ID: 38431592
[TBL] [Abstract][Full Text] [Related]
2. Plasma exosomal
Chen L; Wang K; Li L; Zheng B; Zhang Q; Zhang F; Chen J; Wang S
Future Oncol; 2022 Aug; 18(26):2919-2931. PubMed ID: 35893704
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S
Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570
[TBL] [Abstract][Full Text] [Related]
4. Plasma-derived exosomal miR-4732-5p is a promising noninvasive diagnostic biomarker for epithelial ovarian cancer.
Liu J; Yoo J; Ho JY; Jung Y; Lee S; Hur SY; Choi YJ
J Ovarian Res; 2021 Apr; 14(1):59. PubMed ID: 33910598
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer.
Meng X; Müller V; Milde-Langosch K; Trillsch F; Pantel K; Schwarzenbach H
Oncotarget; 2016 Mar; 7(13):16923-35. PubMed ID: 26943577
[TBL] [Abstract][Full Text] [Related]
6. [Preliminary study on the diagnostic value of serum-derived exosomal lncRNA in epithelial ovarian cancer].
Li YW; Li L
Zhonghua Fu Chan Ke Za Zhi; 2022 Mar; 57(3):198-209. PubMed ID: 35385957
[No Abstract] [Full Text] [Related]
7. Plasma circN4BP2L2 is a promising novel diagnostic biomarker for epithelial ovarian cancer.
Ning L; Lang J; Wu L
BMC Cancer; 2022 Jan; 22(1):6. PubMed ID: 34980005
[TBL] [Abstract][Full Text] [Related]
8. circDENND4C, a novel serum marker for epithelial ovarian cancer, acts as a tumor suppressor by downregulating miR-200b/c.
Liu S; Yuan L; Li J; Liu Y; Wang H; Ren X
Ann Med; 2023 Dec; 55(1):908-919. PubMed ID: 36896567
[TBL] [Abstract][Full Text] [Related]
9. Validation of LRG1 as a potential biomarker for detection of epithelial ovarian cancer by a blinded study.
Wu J; Yin H; Zhu J; Buckanovich RJ; Thorpe JD; Dai J; Urban N; Lubman DM
PLoS One; 2015; 10(3):e0121112. PubMed ID: 25799488
[TBL] [Abstract][Full Text] [Related]
10. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C
PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
[TBL] [Abstract][Full Text] [Related]
11. Exosomal miR-99a-5p is elevated in sera of ovarian cancer patients and promotes cancer cell invasion by increasing fibronectin and vitronectin expression in neighboring peritoneal mesothelial cells.
Yoshimura A; Sawada K; Nakamura K; Kinose Y; Nakatsuka E; Kobayashi M; Miyamoto M; Ishida K; Matsumoto Y; Kodama M; Hashimoto K; Mabuchi S; Kimura T
BMC Cancer; 2018 Nov; 18(1):1065. PubMed ID: 30396333
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer.
Kristjansdottir B; Levan K; Partheen K; Sundfeldt K
Gynecol Oncol; 2013 Oct; 131(1):52-8. PubMed ID: 23891789
[TBL] [Abstract][Full Text] [Related]
13. Macrophages derived exosomes deliver miR-223 to epithelial ovarian cancer cells to elicit a chemoresistant phenotype.
Zhu X; Shen H; Yin X; Yang M; Wei H; Chen Q; Feng F; Liu Y; Xu W; Li Y
J Exp Clin Cancer Res; 2019 Feb; 38(1):81. PubMed ID: 30770776
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic measures comparison for ovarian malignancy risk in Epithelial ovarian cancer patients: a meta-analysis.
Suri A; Perumal V; Ammalli P; Suryan V; Bansal SK
Sci Rep; 2021 Aug; 11(1):17308. PubMed ID: 34453074
[TBL] [Abstract][Full Text] [Related]
15. Plasma exosomal miR-320d, miR-4479, and miR-6763-5p as diagnostic biomarkers in epithelial ovarian cancer.
Wang S; Song X; Wang K; Zheng B; Lin Q; Yu M; Xie L; Chen L; Song X
Front Oncol; 2022; 12():986343. PubMed ID: 36591520
[TBL] [Abstract][Full Text] [Related]
16. Exosomal microRNAs as tumor markers in epithelial ovarian cancer.
Pan C; Stevic I; Müller V; Ni Q; Oliveira-Ferrer L; Pantel K; Schwarzenbach H
Mol Oncol; 2018 Nov; 12(11):1935-1948. PubMed ID: 30107086
[TBL] [Abstract][Full Text] [Related]
17. Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: a meta-analysis.
Li F; Tie R; Chang K; Wang F; Deng S; Lu W; Yu L; Chen M
BMC Cancer; 2012 Jun; 12():258. PubMed ID: 22712526
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the sensitivity and specificity of serum level of prostasin, CA125, LDH, AFP, and hCG+β in epithelial ovarian cancer patients.
Bastani A; Asghary A; Heidari MH; Karimi-Busheri F
Eur J Gynaecol Oncol; 2017; 38(3):418-424. PubMed ID: 29693884
[TBL] [Abstract][Full Text] [Related]
19. The clinical value of the combined detection of sEGFR, CA125 and HE4 for epithelial ovarian cancer diagnosis.
Li Y; Wang ZC; Luo L; Mu CY; Xu J; Feng Q; Li SB; Gu B; Ma P; Lan T
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):604-610. PubMed ID: 32016961
[TBL] [Abstract][Full Text] [Related]
20. Detection of plasma exosomal miRNA-205 as a biomarker for early diagnosis and an adjuvant indicator of ovarian cancer staging.
Zhu Z; Chen Z; Wang M; Zhang M; Chen Y; Yang X; Zhou C; Liu Y; Hong L; Zhang L
J Ovarian Res; 2022 Feb; 15(1):27. PubMed ID: 35183243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
